Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_assertion type Assertion NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_head.
- NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_assertion wasGeneratedBy ECO_0000203 NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.
- NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_assertion wasDerivedFrom befree-2016 NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.
- NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_assertion SIO_000772 21898529 NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.
- NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_assertion evidence source_evidence_literature NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.
- NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.